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1. Executive summary 
This report takes the national imaging facility (NIF) as a case study in how small and 
medium-sized enterprises (SMEs) gain access to national public research 
infrastructure. In May 2015, further funding for NIF was announced under the 
National Collaborative Research Infrastructure Strategy (NCRIS) with $2.93 million 
committed for 2015–2016. However, the Boosting Commercial Returns from 
Research discussion paper released in late 2014 identified industry collaboration as 
an important part of NCRIS and has resulted in member institutes and universities 
refocussing their strategies for SME engagement
1,2
. 
This paper identifies three key areas of concern that currently serve to limit the level 
of engagement by SMEs with NIF research nodes: 
1. Building better and stronger networks 
2. Lowering barriers to engagement at the NIF nodes, including reconciling 
competing motivations of SMEs and academic institutes 
3. Consistent funding for early stage pre-clinical feasibility research. 
First, there is a challenge of making new connections and building collaborative 
networks within the emerging innovation system. A major component of this is the 
lack of knowledge in industry about NIF node capabilities. SMEs are often unaware 
of the capabilities available in the NIF and do not have the resources (e.g. time, 
attention) to search for them. 
Based on 36 interviews with researchers, SME managers and industry experts, this 
research suggests that NIF nodes must prove their relevance to the industrial base 
and this is the primary lever to increase SME engagement with public research 
infrastructure. Fruitful research collaborations will result from investing in outreach to 
build brand identity and establish critical inter-personal connections that will lead to 
new research ideas. This will require increasing the attendance levels at 
practitioner-focused symposia and direct investments in business development 
activities at NIF nodes. 
A second set of problems is associated with engagement. Once potential SME 
partners are identified there are several barriers standing in the way, including the 
high cost of access, lack of incentives for engagement and inflexible IP strategies 
which serve to dissuade SME engagement. More flexible IP strategies, tiered cost 
structures, introductory rates, research open days and the use of spare capacity to 
facilitate small research projects are all ways that nodes can ‘shake up’ the current 
paradigm and inculcate a more collaborative and open environment that might lead 
to interesting technological development projects. A few of these points are worth 
elaborating here. Nodes need to be particularly careful not to dissuade SME 
engagement by taking overly aggressive IP stances.  
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In the early development stages of technology this means not demanding ownership 
of project or foreground IP when there is little actual knowledge of the commercial 
value of the research. Similarly, in later stages of development, institutes have 
opportunities to perform fee-for-service work which is not an opportunity to create IP. 
Pragmatic and reasonable approaches to IP are required to draw SMEs into 
collaborations. Approaches to IP should primarily be business rather than legal 
discussions. In terms of capabilities, there is a dearth of research staff working 
under the facility fellows (and, in some limited cases, inadequate equipment) which 
is a capacity issue that limits nodes’ ability to engage in more industry projects. 
Another aspect of the engagement problem for academic researchers is incentives 
that are not aligned toward translational research. This, in turn, creates an inwardly-
focused culture when an outward-facing culture is required to engage with industry 
partners in a timely manner. Changes are needed to make commercial engagement 
more rewarding in terms of career progression for academics. More fundamentally, 
in terms of their approach to engaging SMES, institutions need to recognise the 
potential for many different types of engagement—each requiring different business 
stances. For instance, early-stage and ‘tangential research’ (i.e. ARC linkage grants) 
opportunities with SMEs offer greater potential for discovery and high intellectual 
property (IP) generating potential for institutional players. 
However, SMEs have the most trouble sourcing funding at this stage and the onus is 
on the institute to secure and manage such projects while, at the same time, 
ensuring that they are keeping SMEs well informed about progress and direction. 
Later stage commercialisation efforts offer opportunities for fee-for-service work 
which has low IP potential for the institutes but are something that SMEs favour (now 
at a later stage of development with a better funding profile) and for which they can 
pay commercial rates. These income streams could subsidise other early-stage and 
tangential research opportunities. 
The third issue is funding and this transcends NIF and directly concerns the health of 
the bio-medical innovation system in Australia and the role of the Department. The 
SMEs we interviewed consistently pointed to the severe gap in funding for early pre-
clinical technology feasibility. To remedy this problem we recommend more 
consistent government support in the form of small grant schemes in the order of 
$10,000–$100,000 that do not require matching funds. The ethos behind these 
grants should be short proposals, quick review cycles and quick awards. There is a 
successful model for this type of grant in the USA called the Small Business 
Innovation Research (SBIR) that has been independently verified by researchers as 
providing excellent returns for public investment
3–6
. Currently ARC linkage and 
NMHRC schemes operate on time frames that are much too long, with highly 
uncertain outcomes and low probabilities of success. Matching fund requirements 
are a deterrent. In combination, this serves to deter SMEs with limited resources 
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and great ideas. Smaller and more quickly awarded grants would allow SMEs to 
quickly work through new technology ideas and jumpstart commercialisation efforts. 
In this vein, small block grants that are tied to the use of NIF facilities would be one 
way of remedying the dearth in funding at critical early stages and to directly 
increase SME engagement with the nodes. Finally, the Department should aggregate 
the disparate funding schemes maintained at the state and federal level into an up-
to-date web portal to help SMEs find current funding sources. This portal should also 
help connect SMEs to venture capital. 
An important point to make about this research is that we did not limit our interviews 
to SMEs that currently use NIF resources. Instead, we targeted SMEs in the bio-
medical industry that may or may not have direct need for imaging per se, but that 
do have a need to engage with research institutions to drive innovation activities by 
accessing equipment and capabilities. 
From this approach we can see that the tendency to engage with institutional players 
like those represented by NIF nodes, and the barriers facing SMEs, are a more 
pervasive challenge than those facing just NIF. The findings from this report should 
have applicability across the broader investments made under NCRIS. 
2. Background and scope 
Access to government-funded advanced scientific infrastructure (e.g. equipment, 
facilities and staff) is a way that small and medium-sized enterprises (SMEs) and 
start-ups can jumpstart and extend their innovation activities. Since SMEs comprise 
most economic activity in Australia, connecting these businesses to government-
funded advanced scientific infrastructure is important to the proper functioning of the 
Australian national innovation system as a whole. 
This report sought to uncover the current state-of-play with regard to SME 
engagement with national imaging facility (NIF) research nodes. The report identifies 
hurdles preventing collaboration and suggests potential pathways for increasing 
collaboration levels. The report takes a broad-based perspective with regard to 
small business engagement with government- funded infrastructure. It is based on 
interviews with many entities, including those directly involved with NIF nodes. 
We interviewed small-business executives, industry trade group leaders, as well as 
NIF node directors and facility fellows in order to paint a clearer picture of the status 
of SME engagement and the potential rewards and challenges. 
The report is not intended to be a prescriptive document. It seeks to identify 
engagement successes / shortfalls that represent potential areas to leverage / 
improve. We do not aim to make prescriptive recommendations about how SME 
engagement should be ‘fixed’, but rather to provide material for subsequent policy 
discussions within the NIF administration, NIF nodes and the Department of 
Industry, Innovation and Science. SMEs may also find it useful to help them 
understand how other firms view engagement with research entities like those 
represented by the NIF nodes. 
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3. Approach and Research Method 
The research is interview-based qualitative assessment. Consultations with the 
stewards inside institutions that house government-funded equipment were 
organised to gain an ‘inside out’ perspective on the issue of SME engagement. 
Significant research effort was dedicated to obtaining an ‘outside in’ perspective 
from various small businesses in the biotechnology and medical fields that are 
either directly involved with NIF facilities or that could potentially be. A list of the 
final set of interviews is shown in Table 3.1. 
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Table 3.1: Interviews conducted 
 Name Role(s) Organisation(s) Type of 
org. 
Service(s) / product(s) / 
Knowledge area(s) 
1 Peter Beven Corporate 
Educator 
QUT Business School Research 
institute 
Strategy, business planning, 
innovation and 
entrepreneurship 
2 Helen 
Chenery 
Executive 
Dean, Health, 
Science and 
Medicine 
Bond University Research 
institute 
Language neuroscience, 
Research management 
3 Steve 
Wesselingh 
Executive 
Director 
South Australian Health 
and Medical Research 
Institute (SAHMRI) 
Research 
institute 
Health and medical research 
imaging 
4 Perry Bartlett Director Queensland Brain 
Institute 
Research 
institute 
Molecular neuroscience, 
research management 
5 Annie Chen Scientific & 
Engagement 
Manager 
National Imaging Facility 
(NIF) 
Research 
institute 
Research infrastructure 
administration 
6 Susan Porter Manager Preclinical, Imaging & 
Research Laboratories 
(PIRL) section of the 
South Australian Health 
and Medical Research 
Institute (SAHMRI) 
Research 
institute 
Research management, 
veterinary pre-clinical imaging 
7 Anonymous Facility Fellow National Imaging Facility 
(NIF) Node Anonymous 
Research 
institute 
Imaging, radiology 
8 Karine 
Mardon  
Facility Fellow National Imaging Facility 
(NIF), Centre for 
Advanced Imaging (CAI) 
Research 
institute 
Molecular Imaging 
9 Anonymous Facility Fellow National Imaging Facility 
(NIF), Node Anonymous 
Research 
institute 
Cyclotron and radiochemistry 
10 Rebecca 
Osborne 
Deputy Director National Imaging Facility 
(NIF) Centre for 
Advanced Imaging (CAI) 
Research 
institute 
Lead node in the NIF network 
11 David 
Reutens 
Centre Director National Imaging Facility 
(NIF), Centre for 
Advanced Imaging (CAI) 
Research 
institute 
Major facility in the NIF 
network 
12 Ian Brereton Node Director National Imaging Facility 
(NIF), Centre for 
Advanced Imaging 
Research 
Institute 
Research-funding, 
commercialisation, industry 
engagement strategy 
13 Dr Tim 
Kuchel 
Node Director National Imaging Facility 
(NIF), Large Animal 
Research Imaging 
Facility (LARIF) 
Research 
institute 
Large animal imaging 
research 
14 Anonymous Area Director South Australian Health 
and Medical Research 
Institute (SAHMRI) 
Research 
institute 
Small animal studies 
15 Prab Takhar Director Molecular Imaging and 
Therapy Research Unit 
(MITRU) of SAHRMI 
Research 
institute 
Radio pharmaceuticals 
research and development 
and products 
16 Lawrence 
Bremner 
Deputy 
Director, 
business and 
partnering 
Centre for Integrated 
Preclinical Drug 
Development (CIPDD) / 
TetraQ Pty Ltd 
Research 
Institute 
Therapeutic drug 
development and 
commercialisation, 
entrepreneurship, innovation, 
venture capital 
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 Name Role(s) Organisation(s) Type of 
org. 
Service(s) / product(s) / 
Knowledge area(s) 
17 Amy 
Gathercole 
Managing 
Director 
COMPATH SME Health monitoring and disease 
surveillance programs in 
animal research laboratory 
facilities. 
18 John 
Greenwood 
CEO Skin Pty Ltd (LARIF 
collaborator) 
SME Cultured composite skins 
(CCS) 
– CCS is designed to abolish 
the need for skin grafting by 
producing cultured layers of 
dermis-derived cells 
19 Nicky Milsom Independent 
consultant, 
Former CEO of 
medical device 
company 
Anonymous SME Imaging technology, 
entrepreneurship, venture 
capital, funding 
20 Nigel 
Greenwood 
Managing 
Director 
Evolving Machine 
Intelligence Pty Ltd 
SME Modelling, computation, data 
mining, systems biology 
21 Alan Taylor Executive 
Chairman 
Clarity Pharmaceuticals 
(CAI collaborator) 
SME Radio pharmaceuticals 
22 Anonymous COO & Co- 
founder 
Anonymous SME Pharmaceuticals 
23 Garry 
Redlich 
CEO Implicit Bioscience Pty 
Ltd 
SME Clinical-stage immune- 
regulatory molecules for 
treating cancer and 
autoimmune diseases 
24 Anonymous Technical 
Manager 
Anonymous SME Agricultural biotechnology 
products, university 
collaborations 
25 Helen 
Roberts 
CEO Dendright SME Pharmaceutical drugs to fight 
autoimmune conditions, 
including rheumatoid arthritis, 
MS, diabetes 
26 Neil 
Finlayson 
CEO Admedus Vaccines Pty 
Ltd 
SME Prophylactic and/or 
therapeutic DNA vaccines for 
infectious diseases and 
cancers in humans 
27 Anonymous CEO Anonymous SME Aortic devices for heart failure 
and drug-resistant 
hypertension 
28 Richard Aird CEO Magnetica Limited SME Magnetic resonance coils and 
radio frequency antennae for 
medical imaging equipment 
29 Anthony 
Maloney 
CEO Melcare Biomedical Pty 
Ltd 
SME Honey-derived medical 
devices for treatment of 
chronic medical conditions 
30 Barry 
Thomas 
CEO Cook Medical Australia SME Interventional technologies 
and therapies for treating and 
diagnosing cardiovascular 
disease and also reproductive 
health and urology 
31 Angus 
Forster 
CEO, COO Vaxxas SME Nanopatch vaccine delivery 
system 
32 Clarence N CEO, Bond Wireless Bond SME Entrepreneurship, venture 
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 Name Role(s) Organisation(s) Type of 
org. 
Service(s) / product(s) / 
Knowledge area(s) 
W Tan Professor University 
Singularity University 
(Singapore) 
capital, university systems 
33 Tim Cragg CEO Vascular Enhancement 
Technology 
SME Medical-device 
commercialisation 
34 David 
Hughes 
CEO BioPharmaceuticals 
Australia (BPA) 
Trade 
group 
Grant-funding expertise, 
manufacturing facilities 
35 Mario 
Pennisi 
CEO Life Sciences 
Queensland 
Trade 
group 
Funding, venture capital, 
networks 
36 Greg Beaver Founder Health Tech Innovation 
Queensland 
Trade 
group 
Networking organisation to 
collaborate and inspire health 
tech entrepreneurship, 
commercialisation and 
investment. 
Notes: Research Institutions: 16, Trade groups: 3, Small business: 17, Total interviews: 36 
 
4. Findings 
The interviews uncovered several potential problem areas that may currently 
undermine collaboration. These are grouped into two areas which are: (1) 
establishing new connections and better networks and (2) the mechanics of 
engagement. Each of these areas are discussed below.  
4.1 Establishing new connections and better networks 
There was a consistent recognition that, in order to facilitate collaborative 
innovation opportunities,  SMEs and institutional players must first find each 
other—a problem of search. Second, making connections between SMEs and 
institutions is not as easy as one might think, particularly for ‘outsider’ firms that 
are not currently connected to the university locations which house NIF 
equipment. Third, the institutional players can do more in terms of attracting 
SMEs to their door by ‘putting on a commercial face’. These three points are 
discussed below. 
4.1.1 Search: connecting institutes with industry partners 
An initial problem in terms of connecting institutes to potential industry partners is 
the lack of effective communication about NIF node capabilities to industry. 
Small business and trade group executives generally characterised this issue as 
a problem of institutional outreach. They viewed the efforts on the part of 
institutes as being inadequate in terms of making interesting connections that 
lead to novel research collaborations. 
Many of these executives thought that institutional researchers should strive to 
spend more time outside the laboratory in order to cultivate relationships with 
industry. Several of them suggested that institutional attendance at translational 
and practitioner conferences that were more commercially focused was 
appropriate. Preeminent life sciences conferences like the Bio International 
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Convention and the DIA annual meeting were suggested as premier networking 
opportunities which the NIF should focus its attention on. 
Another suggestion was to develop dedicated business development managers 
who could conduct more consistent outreach activities at the institutional level in 
an attempt to build bridges between academia and industry. According to one 
institutional executive, they need to spend lots of time and effort ‘networking the 
networks’. Another executive challenged public research entities to ‘make 
yourself relevant’ by ‘showing others what you’ve got’. They obviously consider 
the onus being on the NIF in terms of outreach. 
The institutes are the interested party that must invest in outreach simply 
because SMEs are resource limited. SMEs are very focused on achieving 
commercial milestones related to their limited product/service set and do not 
have spare personnel, funds or time available to seek out potentially novel 
partnerships—particularly if they are tangential to their current product focus. 
Consequently, they may be completely unaware of institutional capabilities— 
even when those capabilities may directly support their efforts or help to short-
circuit innovation activities by providing unique product development pathways or 
insights. 
Node directors and research fellows can play significant direct roles in building 
networks. Characterising the inter-personal connections that underpin strong 
networks, one NIF facility director we interviewed is personally engaged in as 
many cross-institutional roles as possible, including serving on various boards 
and ethics committees in order to become very aware of the activities of others 
in the network. Consistent networking along these lines helps to elevate the 
node in the consciousness of network partners and improves the chances of 
being recommended in future interactions. However, these roles are a luxury 
when the operators of specialised equipment in the nodes are often on short-
term contracts due to funding limitations. There is a role here for government to 
dedicate funding towards business development capabilities in NIF and within 
NCRIS more generally. 
Another benefit of these networking activities is that, over time, it helps to 
position these institutes as knowledge brokers within the industry network. Such 
brokers are privy to more diverse sets of firms and information, and this 
increases the opportunity to play matchmaker to facilitate truly novel research 
partnerships in which they can play a key role. Some facility fellows were found 
to have deep connections with industry, often resulting from prior industry 
positions with key imaging technology businesses such as GE and Siemens. 
Moreover, some fellows tended to have diverse and international connections 
that represented substantial and unique opportunities for collaboration. 
4.1.2 Ease of making connections: insiders and outsiders 
At this point, it is necessary to recognise that some SMEs that exist in the biotech 
/ biomedical space do not have a problem locating and utilising institutional 
capabilities. During our interviews we discovered two basic types of SMEs. The 
first type is insiders. Insiders are spinout SMEs founded on IP that was originally 
created at certain universities. These firms have intimate knowledge of the 
university capabilities. They often have employees who hold dual appointments 
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in the firm and the academic institution. Insiders were repeatedly observed as 
obtaining preferential access to equipment—often to the bemusement of 
delighted  executives who reaped the benefits. One executive called this power: 
‘bypassing the bureaucracy’. Another executive said that spinouts get special 
treatment and even went as far as claiming that the institutional players are 
incentivised to ‘bend the rules’ for these spinouts. 
Collectively this provides insiders with a tremendous advantage. 
Some of the spinouts characterised themselves as ‘virtual’ firms. This type is 
even more embedded in the university infrastructure because they are often 
simply projects which are wholly conducted by institutional researchers. For 
virtual firms, ‘external’ involvement comes from funding (often by third parties 
including multinational drug firms) and senior management (themselves often 
former university employees). Consequently, this type of company is quite 
comfortable with access to university infrastructure and is aware of what is 
available in terms of research arrangements. See Figure 4.1. 
A typical example of an insider SME is a company called Magnetica. This 
company spun out of the University of Queensland as a result of IP associated 
with the design of magnets for MRI machines. While the company has needed 
to navigate collaborative challenges within UQ, they are also very aware of the 
capabilities that exist within the university and how UQ can assist them with 
technological development. Most recently, Magnetica has used the UQ Centre 
for Advanced Imaging to calibrate their new generation of MRI machines. 
Figure 4.1: Two types of SMEs 
 
The second type of SMEs is outsiders. These are firms which do not have pre-
existing ties with the institutes housing scientific infrastructure. They are often 
unaware of the institutional capabilities that can help to accelerate their 
innovation processes. This situation is best characterised by the example of a 
SME CEO near Brisbane who was unaware of any of the equipment available a 
NIF node just a few kilometres from his office. This is despite the fact that this 
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technology is directly applicable to his current commercialisation efforts and 
desire to conduct in vivo imaging of immune response to cancer therapeutic in a 
rat model—something well within the capabilities of the CAI Node. 
Beyond the difficulties involved in locating relevant capabilities, engaging with 
institutes and universities was viewed as being a challenging process by many 
outsider SME executives. Although, in many cases, SMEs are interested in 
engaging with institutes, finding any spare financial resources available in order 
to engage is problematic. Grant schemes that support their involvement are 
seen as fleeting and ever-changing with a ‘clock-speed’ not appropriate for 
SMEs trying to commercialise technology. For example, the ARC linkage grant 
scheme can take over a year from initial discussions to finding out the result of a 
grant application, and then the probability of success is less than 30 per cent. 
Outsider SMEs crave better knowledge of the funding available and means by 
which to access it. 
Also, not having the benefit of prior direct knowledge of capabilities and 
personnel makes it hard for outsider SMEs to know how the institution might 
help them with their particular technology development efforts. Weary of past 
intellectual property negotiations that went sour, these SMEs are also skittish 
about engaging because they do not want to lose control of their technologies. 
Case study  4.1 
One anonymous small business CEO typifies the challenges faced by outsider 
organisations. After finding the university environment in New South Wales too 
constraining to support development of a new cardiovascular device, the CEO 
moved to Queensland in order to seek (and ultimately win) a Queensland 
Government innovation start-up grant. This grant funded the development of a 
prototype, preliminary animal studies, market research and business planning 
efforts.  However, according to this CEO, lack of a core life sciences and 
medical devices ‘hub’ within Brisbane made it hard for his company to get 
subsequent traction for the device. He is frustrated with existing trade groups 
which are either too focused on pharmaceuticals (rather than devices) or are 
highly institutionalised and cater to institutional players rather than small 
businesses. Over the past few years, a significant amount of time has been 
focused on chasing grant money while the development of the product 
languished. He is also frustrated with the current state of funding, stating that it 
is ‘hard to get a finger what’s going on…there are state schemes and federal 
schemes and they are changing quite a bit’. 
Although he is aware of the Advance Queensland Grant scheme, he feels 
without an existing partnership or shared IP with an institutional player, he will 
be disqualified from the scheme, along with other firms in the same situation. 
He eagerly awaits more details on the small business portion of the Advance 
Queensland scheme and hopes that this will not be the case. At the same time, 
the CEO is very cautious about engaging with institutional players because of 
the high costs associated which can ‘quickly eat through your funding’, together 
with the danger of losing IP position. 
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Connecting with outsider organisations represents a unique opportunity for 
institutional SMEs, particularly in the facilitation of novel research. Outsiders—
due to their inherent distance from core institutional activities and their different 
perspectives cultivated outside the (particular) institutional realm—represent 
opportunities to facilitate truly novel discoveries by bringing fresh perspective 
and information to the research efforts of the institution. This is the type of 
relationship that should be sought out by institutes to, as one particular centre 
director put it, ‘facilitate unknown-unknowns’. These are the type of connections 
that can lead to projects where new uses for equipment are dreamt up and 
attempted. One approach to facilitating this sort of collaboration is to ‘research 
open days’ that allow access to equipment at little to no cost to interested 
SMEs. The Fraunhofer Institutes in Germany often use these open days to 
engage new business partners and find novel uses for their technology. 
4.1.3 Putting on a commercial face 
Another problem relates to the perceived seriousness of institutional players to 
engage in industry partnerships. SME executives were interested to discover 
how much industry work institutional researchers ‘really want to do?’ The answer 
to this question lies in the way in which the institutes present themselves; we 
were able to find examples of organisations that were investing in state-of-the-
art equipment which offers a one-stop-shop for customers, procuring the 
international credentials that provide confidence in the facility’s operations, and a 
significant web presence that signals to the business community a serious 
dedication to collaboration. 
4.1.3.1 One-stop-shop 
The Molecular Imaging and Therapy Research Unit (MITRU) at the South 
Australian Health and Medical Research Institute (SAHMRI) has invested 
heavily in establishing ‘gold- standard’ facilities to support the development and 
translation of radiobiological compounds. Housing SA’s first cyclotron, they 
have been successful in obtaining Therapeutic Goods Administration (TGA) 
production licences and GLP certification in order to establish themselves as a 
premier production facility for radioactive tracer compounds. They have even 
invested in state-of-the-art positive air-control monitoring systems for their clean-
lab production facilities that are above standard. Pre-clinical imaging equipment 
is within reach in the facility and further investments are slated for clinical 
imaging laboratories. The director of the facility argues these investments are of 
‘world-class standard’ and are specifically designed to appeal to global industry 
players by providing the complete breadth of services required to develop and 
commercialise a new compound. This approach is strongly tied to attracting 
significant international project obligations at MITRU.  
With regard to the NIF nodes, LARIF has a rather unique capability of having an 
operating theatre collocated with imaging equipment and this is something that 
should be further leveraged through additional investment in equipment. The 
facility desires a dedicated cardiac catheterization (cath) lab that would provide 
unique research opportunities to implant, test and monitor cardiac products in 
the pre-clinical environment in one single location. The LARIF facility manager 
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noted the ‘peace of mind’ and ‘ease of use’ that this ‘one-stop-shop approach’ 
would provide to industrial collaborators. 
4.1.3.2 Certifications and accreditations 
Another important element of projecting a commercially-friendly front to industry 
involves international certification. Accreditations like Therapeutic Goods 
Administration (TGA) licences, Good Laboratory Practice (GLP) certification, 
Good Manufacturing Practices (GMP), ISO standards such as 9001 
(management) and 1705 (testing) and Association for the Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) demonstrate to 
industry players that research, testing and production activities (where 
applicable) are up to international standards. This, in turn, leaves no room for 
doubt as to the quality of work that may be conducted at the facility. 
4.1.3.3 Web presence 
Another recognised area for improvement by SMEs and industry players alike is 
how institutes present themselves on the web. This criteria has less to do with 
having an exhaustive content listing than it has to do with presenting a webpage 
that ‘looks like’ one a well-respected professional firm would have. The internet 
is often the first port of call for curious SMEs and could be a singular failure 
point in establishing new collaborative relationships. A poorly designed website 
could be the first and last point of contact a potential research partner has with a 
research institute. 
4.2 Mechanics of engagement 
Several specific problems were uncovered which govern the mechanics of 
engagement. 
These include: high costs and difficulty finding financial support to engage in 
collaborative research; the sometimes excessive and severe approaches to 
intellectual property; capacity issues (e.g. scientific staff and equipment); 
incentives for institutional researchers that do not align with commercial 
collaboration; misalignment of timing and urgency between institutes and small 
business; and an overall need to acknowledge that different business stances 
are required in different collaborative situations. Each of these areas is covered 
below. 
4.2.1 Costs and finance 
Cost of access and funding to support research were themes that were 
repeatedly described by SMEs as being problematic. The costs of accessing 
institutional capabilities was characterised by many executives as being high; a 
few thought costs were exorbitant and admitted that it was a reason steering their 
collaborative activities away from institutional players in Australia. Costs appear 
to drive some SMEs toward overseas universities and industry (instead of 
Australian academic) collaborators. These moves were characterised by SME 
executives as being both financially and temporally motivated. The costs of 
conducting similar work scope with these other entities was characterised as 
being affordable in comparison to university rates in Australia—even taking into 
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account the federal R&D tax credit. Some SMEs chose to collaborate with 
industrial partners because they exhibit qualities of expediency and efficiency. 
Industrial collaborators were considered to be much more responsive and more 
likely to achieve the desired results within the limited funding available, as well as 
the pre-determined schedule. SMEs also highlighted the cost disadvantage of 
accessing Australian researchers. 
Overhead levies on contract research can be as high as 60 per cent when pricing 
labour and SMEs were of the opinion that universities used the commercial rates 
charged as an opportunity to cross-subsidise other research activities. One 
node director specifically acknowledged this practice and identified university 
overhead structures as the major culprit behind missed business opportunities 
with SMEs, saying: ‘We’ve lost business because of it....they stop talking to us.’ 
Another finding was the demand for tiered or flexible rate structures for SMEs to 
access institutional capabilities. Some executives considered the practice of 
charging SMEs the same rate as multinational corporations as very unfair. They 
stated that this practice has a high likelihood of dissuading SMEs from engaging 
with certain institutes. Among the executives, there is a desire for conciliatory 
and flexible rates. A repeated request we heard was for structured (and 
transparent) tiered rate structures that would give some preferential treatment to 
SMEs and take into account their lack of resources and largesse in comparison 
with larger, established firms. To support this idea, we found evidence that 
supported the fact that institutional players who seemed to have developed the 
most robust industrial partnerships did so by initially offering concessions on 
costs. One node director discussed introductory rates or ‘mates rates’. These 
were described by one facility manager as a way of getting over the first contact 
hurdle. According to one manager, the basis of fruitful long-term relationships 
was getting SMEs in the door and exploring the particular problem they are 
trying to solve—even if this first interaction involved some large cost 
concessions. The manager described their careful consideration of project 
scope in terms of the budget available to the SME; working closely with the SME 
to achieve results with the available budget. After securing an initial project in 
this way, the manager argued that additional collaborative work ‘always followed’ 
such good faith efforts on the part of the institute. 
 A repeated problem cited by most SME executives (and also astute institutional 
executives) was the poor state of funding for start-ups in Australia. The 
comments about this ranged from the lack of appropriate venture capital (VC) 
funding in Australia to frustration about the ephemeral grant schemes at the 
state and federal level that were viewed as being highly politicised and often too 
slow to be of value in the commercialisation process.Regarding VC (and as 
recently reported in The Australian Financial Review), Australia as a whole 
spends less on R&D than some individual corporations and the level of 
commitment to Australia VC funds dropped to $120m—down 20 per cent from 
last year
7
. Investments into life science businesses were worse with an 
estimated $60m invested by VC funds in 2013–14. One SME executive we 
interviewed characterised Australian technology VC as almost ‘non- existent’ 
and that any that is available is ‘extraordinarily unimaginative’ because investors 
exhibit a long history of risk aversion and investing only in the later stages of 
product development where risks of loss are minimised. 
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In light of the limits of VC, many called for more federal and state grant schemes 
as solutions to fill the gap in funding. In Queensland, many executives lamented 
the demise of the Innovation Start-up Grants scheme. Grants like this provide 
funding in the order of $10,000–$100,000 in investments—a crucial amount of 
funding to support proof-of-concept studies. This level of funding was argued by 
several executives as being a crucial stepping stone that is desperately needed 
to progress nascent product ideas into the pre-clinical efficacy stages of 
development. In this way, they are then attractive enough to draw the high levels 
of funding required to move through from pre-clinical and clinical trials, and into 
product production. As one executive put it, funding helps ‘develop the 
technology up to a point that it is able to draw between $5m and $10m of 
outside investment’. The recently announced Startup Queensland funding—part 
of a broader $180 Advance Queensland grant program—will no doubt help to fill 
this gap. The program will provide $52 million to start-ups: $12 million to create a 
Queensland Commercialisation Program that will support proof-of-concept 
projects and $40 million devoted to business development
8
. 
 However, according to small business executives, the problem with many of the 
grant schemes was the requirement for matching funds. The Startup 
Queensland fund will require 50 per cent of matching funds
9 
which is a major 
problem for firms with early-stage technology that lacks established feasibility. 
There is a desire for funding that either has no matching cost requirement—like 
that of the US SIBR program which even provides for a small profit margin for the 
firm over the life of the grant—or manageable cost-sharing splits that 
appropriately consider the value of in-kind contributions (i.e. labour and 
expertise—not just cash). 
Figure 4.2: Early stage funding gap 
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The Australian funding environment is particularly challenging which has resulted 
in some SMEs seeking finance from international sources. For instance, one 
executive stated that they are seriously considering relocating to Belgium as the 
government there has recently made hundreds of millions of dollars available to 
bridge the pre-clinical to clinical funding gap. According to the interviewee, this 
incentive has enticed large firms like GlaxoSmithKline to situate a 400-person 
facility in this country. 
4.2.2 Intellectual Property 
The treatment of intellectual property was a foremost concern for SMEs. Many 
executives interviewed for this report said that university IP-management 
strategies were antiquated and misdirected. One executive argued that the days 
where universities generated all the IP are long gone, citing rapidly improving 
(and affordable) computing capacity in the order of teraflops being available to 
‘garage inventors’. Indeed, the landscape is shifting rapidly so that SMEs with 
no strong prior relationship to universities are cropping up with their own IP 
which is completely unaffiliated with a university. The innovation literature has 
long considered the linear model of research commercialisation to be an 
incorrect representation of innovation and this is certainly the case for the 
examples of innovation we identified in this report. Valuable IP does not get 
produced exclusively in research institutions so that it can be developed in 
collaboration with industry partners. 
Although SMEs are interested in accessing institutional equipment and 
capabilities, they are not willing to give away their IP position to access 
university technology. SMEs—and any other firms which owns their IP outright—
are highly suspicious of starting to negotiate their position with universities if they 
own any foreground / project IP. In such cases, many executives cited instances 
where they felt it was preferable to ‘walk’ away from the table and seek 
alternative collaborations. Mostly this sentiment was expressed by outsider 
organsiations that are not already ingrained in the university system (refer to 
Figure 4.1). Outsiders are unlikely to enter into a collaborative project if there is 
a chance that it will erode their IP position. If a project IP ownership stance is 
adopted by the institutional player, it seems that it will almost always dissuade 
SMEs from engaging in a collaborative project. While some firms seemingly did 
not have issues with IP in terms of their institutional collaborations, it appeared 
that only the insider organisations espoused this view. Insiders were more likely 
to take a less proactive stance on IP because they have faith (based on the 
inter-personal trust established as a result of being highly embedded in the 
institute) that a reasonable IP negotiation process could take place at a later 
date. Consequently, these firms were more comfortable letting the institute claim 
ownership of the project IP because they knew that they would receive 
‘sweetheart deals’ (as one CEO put it) in the licencing fee negotiation if the 
product has commercial viability. 
SME executives cited the need for institutes to practice a more flexible approach 
to IP. One current NIF-node collaborator SME said institutional players need to 
‘let the IP breathe’ referring to the fact that most IP will not translate into 
commercial success and therefore should not be locked up prior to determining 
its commercial potential. Another executive argued in favour of leaving the 
lawyers out of the discussion until the commercial potential of the IP can be truly 
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determined, and only at that point enter into negotiations regarding what to do 
with it. This interviewee said: ‘IP management is not a legal issue; it is a 
management issue’ and went on to cite several examples of how more relaxed 
IP strategies are becoming the norm at the institutional level—referring to the 
‘Stanford model’ and the ‘Singapore model’ where the ethos is ‘to give the IP 
away’ and see which aspect of it is commercially viable. Australian universities 
that interviewees mentioned as ‘getting it right’ and ‘moving in the right direction’ 
in the IP space were Macquarie University and University of Western Sydney. 
While initiatives like the new DIS IP toolkit can help to better inform researchers 
and SMEs about IP management, they are of little value if the universities 
themselves are very traditional and encourage risk averse polices on IP, which 
researchers must comply with. 
4.2.3 Capacity: people and equipment 
One critical issue is the capacity of NIF nodes to engage with industry 
collaborators, with a primary problem being staff. One facility fellow noted the 
challenges associated with obtaining and training staff to the capability level 
expected by outside firms. This stems from lack of foresight in terms of the 
operational budget in order to support long-term contract hires. Instead, at some 
nodes at least, one-year contracts are being offered. The inability to offer 
employment security via multi-year employment contracts (‘5 year plus 5’ were 
mentioned as a useful heuristic) dissuades internationally-qualified professional 
staff from applying for staff positions at Australian NIF nodes. Often the best-
suited candidates are living overseas and will not consider moving their families 
under such insecure employment terms. Consequently, although the facility 
fellow positions are securely funded positions paid by NIF, these fellows are 
hamstrung to hire and develop the people necessary to create a truly robust 
capability to handle internal research agendas, let alone have the capacity to 
support additional industrial collaborations with SMEs. 
Another facility fellow discussed how one current collaborative project is 
completely monopolising the capacity in their research area. They said, in no 
uncertain terms, that there is no capacity to support more industry collaborations. 
According to this fellow: ‘There are barely enough resources available to digest 
what happens on a weekly basis with the client and to undertake any self-
directed basic research.’ The failure of nodes to attract capable and talented 
staff because they are only being offered short-term contracts is potentially a 
serious issue that will undermine their ability to conduct basic science, as well as 
support industry collaborations. While the basic science problem has been 
highlighted elsewhere, we draw attention to the additional problems of creating 
and sustaining industry collaborations unless better job security is written into 
the funding of NCRIS centres in general. There is a clear role for government 
funding here. 
In other cases it is equipment, not staffing, that is hindering SME engagement. 
The LARIF facility in SA has a long history of successful industry engagement 
but is currently turning away work because of antiquated equipment and 
equipment needs that have not been fulfilled. Outdated magnetic resonance 
(MR) equipment cannot run the latest imaging sequences and those sequences 
it can actually run take four times longer than new equipment. A new 3 Tesla 
(3T) MR system is needed and could support neurobiological imaging that 
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represents a unique growth area for the facility. Furthermore, this facility is one of 
the few that has operating theatres and imaging equipment housed within the 
same facility—a unique capability which they want to expand upon by installing 
a cardiac catheterisation (cath) lab. Investments like these will enable existing 
partnerships to be expanded and new partnerships to be formed. 
4.2.4 Incentives 
Another major issue related to building robust networks is the misalignment of 
logics between institutions and commercially-focused SMEs. Both business 
executives and institutional members recognised this as being a problem. A 
particular challenge occurs when infrastructure is collocated at purely academic 
institutions; the researchers (who are stewards of the equipment and the 
research conducted on it) operate under career progression paradigms that 
reward journal publication outputs. For them, commercial outcomes are 
considerably less important. Many academics who were interviewed (including 
their executives) consider short- term commercial work as a distraction from 
discovery and publication. Commercial work is considered to be at odds with 
their dominant logic. This focus on journal articles and competitive grant 
success is deeply ingrained in the university system. As an example, one 
interviewee mentioned the University of Queensland Q-index which is a 
dashboard of individual academic performance over a 7-year period. It measures 
an academic’s career in terms of journal articles, books and book chapters, 
research student supervisions and grants, and calculates a single number that 
can then be compared with other faculty members. While industry research 
contracts can be included as a grant, other forms of collaboration and 
engagement are not covered by the Q-index. For example, industry reports—
regardless of how influential they were—are given a score of 0. 
Some executives argued that a broader set of measures are required to 
potentially reward academics for patenting and translational research—a similar 
problem noted in the UK as highlighted in the recent Dowling Report
10
. 
Interviewees argued that introducing incentives for academic researchers to 
engage in industrial work, and somehow valuing the outputs of such 
collaborations on an equal footing as publication, would be one way to increase 
levels of collaboration between nodes and industry. Shifting the way that 
university performance is measured in the research assessment exercise is 
probably the only long-term solution to changing internal performance incentives. 
4.2.5 Timing and urgency  
Another criticism of academic logic vis-à-vis accommodating industrial 
collaborations is the general lack of expediency exhibited by researchers and 
the tendency to stray far from the original research question(s). Although these 
are valuable attributes to support basic science, these same attributes actually 
dissuade SMEs from engaging academic researchers in their commercialisation 
activities. Many executives expressed how they kept anything that was on the 
scheduled ‘critical path’ away from academic intuitional influence. This is 
because the impetus for SMEs to engage is driven most often by commercial 
motivations: a ‘technical problem’, an ‘immediate problem’ or to ‘get a leg up on 
a new market’—all of which are time- critical activities. 
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Time criticality is particularly important as SMEs are often in the latter stages of 
commercialisation when time-based milestones related to product efficacy 
become vitally important. During this time, SMEs are highly reticent to relinquish 
any control to others. Therefore, SMEs often want to involve institutes during 
these latter stages, but only to conduct fee-for-service work that supports the 
evaluation of the clinical efficacy of their products. 
 Reflecting this sentiment, one interviewee stated the role of institutions at this 
point was that: ‘You are a supplier and that’s not a [collaborative] relationship’. 
4.2.6 Recognizing the different types of SME engagement 
opportunities 
Various opportunities for SME engagement exist depending on the stage of 
development of the product or device and thus have different funding profiles, IP 
opportunities and timelines. First, the primary logic of the institutional players is 
to participate in the discovery process related to basic research, proof of 
concept and, in some cases, applied research. Such research has the highest 
potential for institutional IP development. After this point, if the technology is 
then housed in an SME (as a spinout, for instance), the institutional role morphs 
to providing fee-for-service support to the SME’s translational efforts which is an 
extremely commercially-minded endeavour. That is, the SME is focused on 
quickly exploring the commercial space and translating successful products into 
commercially viable products for pre-clinical and clinical trials. One executive 
very clearly discussed the need to separate the discovery and translation 
phases, and made a point of arguing that the spinout is the best place to house 
the commercialisation effort because academic researchers are not equipped to 
support commercial efforts. The executive characterised these commercial 
efforts as moving ‘1,000 miles per hour’ with an ethos of ‘fail smart, fail fast’ in 
order to quickly cull ideas that are not working and greatly increase the 
probability of finding a commercially viable product quickly. This logic differs 
greatly from the discovery-based logic of the researchers. 
In later stages of development, institutional players are best positioned to provide 
fee- for-service work. SME executives do not view these as collaborative efforts 
and therefore there is little (if any) opportunity for creating joint project IP. 
Instead, the institute is executing the scope of work articulated by a commercial 
client. While this offers the university no potential for project IP development, it 
does offer a source of revenue that can subsidise other basic research 
endeavours. This approach to fee-for-service work is exemplified by LARIF. They 
provide very basic imaging services to professional clinics when the equipment 
would otherwise be idle, thus providing a valuable service to local practitioners. 
This is truly a marginal-cost activity for the node and helps to cover the 
operational budget without draining node resources. By getting practitioners in 
the door, it provides the potential for future collaborations. 
Many SME executives expressed genuine interest in tangential research 
opportunities that are only loosely aligned with current commercialisation efforts. 
These represent opportunities for institutional IP development. Many SME 
executives discussed ARC linkage and NHMRC grant bids / wins focused on 
developing these tangential opportunities. Several expressed the desire to 
understand more fundamental mechanics of pharmaceutical molecules in vivo 
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or other ‘interesting’ pursuits that help to enhance the understanding of the 
product space while not directly supporting the commercialisation effort. 
Therefore, this type of collaboration is well-suited to the institutional players, and 
is where an iterative and non-linear approach to basic research can thrive. 
However, it is the long timelines associated with the funding schemes that 
support this research that perpetuate this tangential research focus. SME 
executives recognise the one or two-year time frames necessarily mean that the 
projects will not help their commercial endeavours any time soon. However, 
despite the longer-term focus it does not mean that executives are willing to let 
these projects operate in complete isolation from commercial reality. A 
complaint made by SME executives with regard to ARC linkage and NHMRC 
grants is the opaque nature of project management and reporting at the 
university level. Consequently, institutions must make an effort to draw the links 
between the basic science and the commercial outcome space, and ensure that 
the SME sponsor is included (or perhaps leading) this mapping exercise. Figure 
4.3 summarises these different types of SME engagement opportunities 
(including the differing logics surrounding each) with a particular emphasis on 
opportunities for IP development and relationship to SME commercialisation 
efforts. 
Figure 4.3: Aligning institutional roles and IP opportunities with SME efforts 
 
5. Recommendations 
This section summarises the recommendations relating to the NIF nodes—
entitled institutional—and those directed toward the Department of Industry and 
Science—entitled policy. This section focuses on recommendations and readers 
should refer to the prior section for a nuanced discussion of the barriers. 
5.1 Institutional 
The institutional recommendations centre on investing in network building and 
improvements to the engagement strategies. 
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5.1.1 Investments in networks 
The onus is on the institutional players to build awareness of their capabilities 
and expertise. SMEs are time poor, resource constrained, and highly focused on 
particular commercial pathways. Finding these SMEs and bringing them to the 
table will require consistent effort on the part of the institutes to convey their 
capabilities and ‘make themselves relevant’ as one CEO succinctly described 
the situation. SMEs will not just turn up at the door. Opportunities for NIF node 
directors include: 
 investing in business development and marketing managers 
 investing in a website presence that exhibits ‘world-class’ status 
 
 investing in certifications and accreditations that portray competency to 
industry 
players 
 supporting attendance and presentations at practitioner and translational 
conferences and symposia. 
5.1.2 Engagement strategies 
There are several issues with regard to improving engagement with SMEs. Five 
main themes are: creative treatment of intellectual property, flexible costing 
strategies, engagement in marginal-cost activities to generate revenues, 
investing in capabilities, and changing incentive structures. Each of these 
engagement strategies are suggested because they may help to support the 
development of new partnerships. 
5.1.2.1 Intellectual property 
There is considerable room for improvement in terms of the treatment of 
intellectual property. When institutes take full ownership stances for project IP, 
SMEs will be dissuaded from engaging with them. More flexible ‘business first, 
lawyers last’ strategies may be a better approach to enticing SMEs to engage. 
IP that is generated in the university environment may or may not have much 
commercial value. A favourite quote of many interviewees was ‘not everything is 
Gardasil’—referring to the highly successful Human Papilloma Virus (HPV) 
vaccine developed invented by Dr. Ian Fraser and spun out of UQ. Another 
executive noted that ‘99.9 per cent’ of IP has no commercial value—referring to 
the relatively small number of research ideas that reach commercial markets. 
Consequently, institutions should approach IP more openly in order to first 
determine if the idea is even feasible, and then decide what sort of commercial 
value it has. At this point, they can then negotiate proper terms for reaping the 
future rewards of the IP with the spinout or SME that is developing it for 
commercial markets. 
Nodes should recognise that the various types of engagement opportunities differ 
in terms of IP development potential, depending on the current stage of 
commercial development (refer to Figure 4.3). In early stages, there is a 
potential for IP development–or at least negotiation–in the early collaborative 
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stages where feasibility is established. As projects move into later commercial 
stages, nodes may be most useful to SMEs as fee-for-service providers where 
there is lower potential for IP development. In later stages of development, SMEs 
have a stronger financial position (having been funded by venture capital, for 
instance) and can afford commercial rates on quick turn-around. As a result, 
institutes should use these opportunities to capture revenue streams that can be 
redirected to basic research. Tangential projects (e.g.NHMRC, ARC linkage) are 
good opportunities to engage in more basic research; as long as the node 
invests the time in developing the proposal and managing the work. SMEs are 
time poor and disinclined to spend large amounts of time pursing grant schemes 
on long timelines with low probabilities of success. Consequently, institutes must 
put forth most—if not all—of the effort in developing, securing and managing 
these projects. 
 In summary, NIF nodes should: 
 make efforts to engage SMEs with a business / commercial mindset: IP 
negotiations should not be the first port of call for new industry engagement. 
This also means that NIF must employ business savvy, commercially-
minded business development people (refer to Section 5.1.1 as well on this 
point). 
 work with legal advisory departments to develop more pragmatic 
approaches to foreground IP that allow SMEs to retain ownership of 
inventions. Focus on developing strategies that firstly establishes the 
viability of the technology and, secondly focuses on sharing potential 
revenue streams resulting from commercialisation. 
 open up and share existing university IP that is currently dormant to 
interested small businesses to spur additional collaboration activities. 
Remember that ‘not everything is Gardasil’ and that universities need to ‘let 
the IP breathe’ to understand its true commercial potential. 
 When conducting fee-for-service activities—those where the industry partner 
is wholly directing the activities—eliminate discussions about foreground IP. 
5.1.2.2 Flexible costing 
There was general acknowledgment amongst the interviewees of the high fee 
structures governing infrastructure access. Several potential opportunities that 
are governed by specific policies of the universities and institutes include: 
 Creating flexible rates for new partnerships, including cost concessions 
which can help to get SMEs in the door and facilitate future activities. 
 Negotiating within the limited budgets of SMEs and trying to develop a 
mutually appropriate scope, with a focus on quickly overcoming the first 
engagement hurdle to establish the feasibility of early-stage ideas that can 
blossom into more fruitful long-term partnerships and revenue for the node. 
 Considering tiered rate structures for both small and large businesses 
(particularly multinational drug firms) since the former are likely to balk at 
commercial rates which may deter engagement. 
 Addressing high overhead mark-ups on university labour which have the 
effect of dissuading cash-strapped SMEs from engaging. 
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   5.1.2.3 Marginal cost activities 
 
In situations where there is spare capacity in node facilities to support additional 
activities, these may represent additional sources of revenue and may also help 
to transform first-time users into longer-term collaborators. 
 A potential source of revenues can be obtained from fee-for-service 
activities that are conducted on spare equipment capacity. LARIF does this 
well by offering equipment time to local clinicians during slack research 
periods. While this is not a high IP value activity, it does represent a 
revenue stream that can subsidise more basic research endeavours. 
 Conduct ‘research open days’ as suggested by several interviewees. The 
Fraunhofer Institute is an example of how open days can be used effectively 
to generate interest in the science activities at the institutes
11,12
, as is the 
Australian Institute of Marine Science
13
. 
 Use spare capacity to facilitate small / basic research projects following a 
similar approach as the US Department of Energy’s user facilities. These 
facilities are open to all interested parties regardless of nationality or 
institutional affiliation. The prioritisation of work and allocation of equipment 
time and staff resources to the projects is wholly determined on the merit of 
the proposals. No fees are 
 charged for non-proprietary work if the user intends to publish their results in 
open literature
14
. 
5.1.2.4 Invest in capabilities 
A major limitation to expanded engagement with industry is sufficiently trained 
and dedicated staff working under each facility fellow. Although this is arguably a 
funding issue,
1
 the inability to offer research staff multi-year contracts is a major 
hindrance to building sufficient capability at the node level to support serious 
levels of industry engagement and this needs to be addressed at the NCRIS 
level. It is particularly obstructive in terms of the ability of research institutes to 
attract international staff to Australia. Therefore, the recommendations are:  
 Find ways to fund longer-term positions that can work with a technical area 
for multiple years. One node collaborator is funding half of a post-doc 
position to support the current collaborative projects. In another example 
outside the biomedical space, Boeing is funding post-doc positions at UQ on 
the premise that Boeing will own all the IP that is generated. Cost-sharing 
strategies like these are one potential source of funding for additional 
research staff that should be heavily pursued. 
 As mentioned in the section about investing in networks (5.1.1), having 
dedicated business development and marketing managers is another 
capability investment that should be considered. 
                                                   
1
 There is insufficient clarity on the node operating budgets year on year to anticipate the available 
resources for hiring staff. 
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5.1.2.5 Incentives 
Node researchers’ career progression rules and incentives are strongly tied to 
discovery and publication, and much less aligned with commercialisation. 
Researchers need to be incentivised and rewarded for industry engagement as a 
potential alternative pathway in order to increase collaboration levels with 
industry. Changes to the Research Assessment Exercise (RAE) may be the best 
way to influence university recognition of successful activities beyond 
publications and grants. 
5.2 Policy 
There are several recommendations that are outside the NIF purview, mostly 
associated with the need for funding grants at both the state and federal level to 
facilitate early-stage commercialisation to compensate for the lack of VC in 
Australia
7
. In the life sciences sector, funding gaps exists along the 
development pathway; however, they are especially acute in the critical early 
stages of development in the order of $10,000 to $100,000 to prove technological 
efficacy. 
 Policy makers should strive to provide some consistency in terms of funding 
schemes and levels of funding available to support innovation in the 
biomedical space. The instability and highly politicised nature of funding 
schemes gives SMEs little leeway to test fundamental feasibility of their 
ideas. Schemes such as innovation start-up grants which have lower 
shared-cost requirements are in demand for serial entrepreneurs and are a 
source of ongoing frustration for them. New schemes such as the Startup 
Queensland fund which provide up to $300,000 in grants blocks will require 
50 per cent matching funds
9
—an untenable proposition for many small 
business firms since they lack the fundamental proof of concept to attract 
outside investment to make up this funding gap shortfall. In this way, a 
financial gap still remains for early-stage research (refer to Figure 4.2). 
Dedicated (read: consistent) grant schemes that cater to SMEs with early-
stage technology ideas that also have links to national innovation priorities, 
such as the Small Business Innovation Research (SBIR) and Small 
Business Technology Transfer (STTR) programs in the USA, can provide 
useful lessons for developing a robust Australian SME grant scheme. Since 
the SBIR program’s inception in 1982 through to 2009, nearly $27 billion 
dollars across 112,500 awarded projects was funnelled into innovation in 
small businesses
15
. Awardees have higher rates of commercialisation 
activity
4
, more readily attract venture capital
6
, have better survival rates, 
and higher and faster growth rates
3
. On the macro level, the SBIR program 
provides net positive benefits to the economy
4
. Sustained investment in 
small business like that demonstrated by the SBIR would stimulate 
additional technological innovation and commercialisation activity, and 
translate into positive economic outcomes in Australia as well. Interested 
readers should review the compelling argument made by David Connell 
from the Centre for Business Research at Cambridge University about the 
steps the UK should follow to implement a SBIR-like program there
5
. 
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 The Department should consider maintaining an up-to-date centralised 
repository of grant and funding schemes to address the criticism, expressed 
by most SME executives, that these type of schemes seem ephemeral. A 
web portal could consolidate grants and funding programs at the state and 
federal levels, and could also provide a listing of active venture capital firms 
and other investment sources SMEs could pursue. 
 One facility director suggested the idea of block grant ‘credits’ that could be 
cashed in to access NIF facilities. This approach has three benefits. First, if 
instituted for some length of time (i.e. over several years) these type of 
schemes e would provide stable funding that SMEs desire. Second, 
because the grants serve as credits for NIF facilities, the money will be 
spent at NIF nodes and will directly increase industry collaboration levels. 
Third, and following on from the second point, the funding would not leak to 
international universities or service providers because it will be spent on 
buying and building Australian research capabilities. 
 Grant proposal processes like ARC linkage have very long lead items and 
are only appealing to SMEs with other (funded) commercialisation activities 
who want to explore tangential research. For SMEs that want to prove the 
conceptual feasibility of a new product idea, these aid packages are not 
beneficial because of the extremely long time frames and low chance of 
grant award success. A more appealing concept to SMEs would be smaller 
block grants with short proposal requirements and funding that can be 
released in a timelier manner in order to test new innovations quickly—an 
essential approach to innovation in the rapidly changing and competitive 
biomedical field. 
6. Limitations of the report and future 
directions 
To promote a more directed strategy for SME engagement with NIF facilities, a 
market segmentation analysis is likely required. This would involve a detailed 
mapping of capabilities (equipment, facilities, people) across NIF nodes to the 
existing industrial base in Australia. The need to understand what areas of 
biomedical research each facility can participate in is an important first step in 
developing a targeted SME engagement strategy, and further, the development 
of a healthy biomedical industrial base in Australia. Moreover, this effort could be 
the starting point for finding alternative uses for imaging equipment that 
transcends biomedical applications. This is because imaging, along with other 
similar modelling and rapid prototyping equipment and techniques, are 
considered innovation technologies (IvTs) which are capable of supporting 
multiple sectors of the economy by enabling rapid testing and evaluation of new 
ideas
16
. IvTs enable firms to more rapidly, efficiently and accurately move their 
ideas from the lab or the desktop into the market. Mapping the capabilities of 
NIF nodes in terms of potential alternative uses in other sectors outside the 
biomedical field is another way to establish new and exciting collaborations. 
Already CAI equipment has been utilised to investigate plant and animal 
materials products—efforts which are tangential to the pre-clinical focus of the 
facility. 
 26 
 
SME access to medical imaging infrastructure 
This strategy mapping effort would take between 6 and 12 months (depending on 
resourcing and funding levels) to conduct and require market analysis and in-
depth interviews with each node facility and research staff. It would result in 
targeted strategies for nodes to pursue in terms of building new relationships 
with the industrial base. This, in turn, would help nodes to make the most 
effective use of their limited funds to invest in outreach, cost concessions, new 
rate structures, etc., that are only recommended at a notional level in this report. 
In addition, this effort would more specifically justify the additional investments 
that are needed in capabilities at each of the NIF nodes to fully exploit the 
industrial engagement opportunities available to them—a criteria which also 
highlights the importance of an industry strategy at the node level as well as the 
NIF. We believe that an industry strategy at the level of NCRIS will be of limited 
value because of the differences across the technological bases represented 
within NCRIS. 
This report points out the challenge of matching publicly funded infrastructure / 
capabilities to a burgeoning biomedical sector which is fast-paced and dynamic. 
The innovation policy and management literature currently recognises ‘open 
innovation’ as becoming the dominant pattern for the development of new 
goods and services in such settings. Open innovation can be defined as the 
purposeful flow of information across firm boundaries in order to jumpstart and 
extend commercialisation activities. Open innovation therefore is  characterised 
by multi-directional flow of knowledge and technology between different players 
in the industrial ecosystem. A useful and influential typology of open innovation 
forms as proposed by Dahlander and Gann
17 
is shown in Table 6.1. In the 
context of SME engagement with NIF nodes, this framework recognises that 
innovation processes can be outbound or inbound, and furthermore, these can 
be monetary transactions (pecuniary) or not. Examples of pecuniary 
transactions include: IP licensing (in and out) and spinout new ventures with 
equity investment. Examples of non-pecuniary openness include: publications 
and free revealing of innovation information to customers, collaborators and the 
like. 
Table 6.1: Different forms of open innovation 
 Inbound innovation Outbound innovation 
Pecuniary Acquiring 
In-licensing, adopting or 
buying expertise or 
technology from external 
sources 
Selling 
How firms protect, appropriate value from, 
and commercialise their intellectual 
property and technological artefacts 
Non-
pecuniary 
Sourcing 
Leveraging existing 
external sources of 
information for 
innovation purposes 
Revealing 
Sending information to the external 
environment selectively, in order to spur 
problem solving or aid in the diffusion of 
innovations 
Source: Adapted from Dahlander and Gann (2010)  
 27 
 
SME access to medical imaging infrastructure 
Emerging industries from unconventional gas production
18
, electric and fuel cell 
cars
19
, computing and biotech
20,21 
all demonstrate the importance of non-pecuniary 
openness in terms of the development of novel innovations in new industries. This is 
because different players in the innovation ecosystem try to stimulate interest from 
commercialisation partners and customers, recognise what complementary 
technologies are available, and are aware of interesting applications that these 
innovations might have in different markets. In the NIF case, adopting such a stance 
with regard to imaging technology will help researchers discover information and 
expertise from the industry sector and encourage new relationships to be built to take 
advantage of innovative technology and source commercial opportunities. Similarly, 
non-pecuniary open innovation will help SMEs more easily find university skills and 
expertise to develop new products and services. While pecuniary forms of openness 
also have a place, in the early stage of industry development firms and institutes will 
benefit from policies and initiatives that support non-pecuniary forms of openness. 
These include employment stability for the researchers so they can maintain the 
external networks they build, and incentives for researchers to make contact with 
industry and build collaborative networks. Making it easier for SMEs to find 
information about research and expertise through websites and open days will also 
help with developing this form of openness. 
The IP management regime can either help support or detract from an open 
innovation stance. The new toolkit developed by the Department of Industry, 
Innovation and Science may support open innovation if it promotes a flexible 
approach to IP management rather than a ‘patent everything’ outlook with lawyers 
dominating IP management processes. However, this may still be insufficient to 
overcome deeply embedded IP management policies within universities. While 
researchers may want to be more flexible, institutional processes need to also 
support this flexibility — particularly with regard to IP. 
7. Conclusions 
In summary, there is great opportunity for SME engagement with NIF infrastructure; 
however, there are currently several hurdles to overcome. Potential hurdles to 
facilitating this engagement include: establishing interesting connections with 
industrial players, and dealing with the mechanics of engagement and use of the 
facilities and funding. On the first point, the value of networking cannot be 
understated. This requires investment on the part of NIF nodes to incorporate (but not 
limit to) investing in outreach which includes: developing business development and 
marketing managers, gaining appropriate certifications and accreditations to exhibit 
quality, building web presence and investing in ‘one-stop-shop’ services. 
On the second point regarding mechanics of engagement, hurdles include high costs, 
inflexible IP strategies, low capacity (people and equipment—the latter in limited 
cases), and misalignment of incentives, timing and urgency. As a result, 
recommendations were made for pragmatic IP approaches; tiered cost structures 
and concessions for first-time users; engaging in marginal cost activities like fee-for-
service business as a revenue-generating endeavour and ‘research open days’ to 
spur interest; investing in capabilities (research and business development); and 
changing incentives to increase rewards for researchers engaging in commercial 
collaborations. In total, these recommendations provide nodes with the tools to 
engage in a diverse set of collaborations (refer to Figure 4.3). 
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On the third point, we made recommendations for funding early-stage research as a 
policy suggestion for state and federal level consideration. SMEs are idea rich and 
cash poor. Fleeting grant schemes and fund-matching schemes all serve to make it 
hard for SMEs with big ideas to access the exquisite infrastructure represented by 
NIF nodes. Hence, recommendations were made for faster-paced small grant 
blocks, and research credits only redeemable at NIF nodes, as ways to entice SMEs 
with interesting technology ideas to ‘come out of the woodwork’ to join in 
collaborative research and development with NIF nodes. We recommend that the 
department help to consolidate disparate research grant schemes and venture capital 
into a single portal. Fundamentally, a stronger and more robust commitment to 
funding technology investments by small business is needed on the state and 
national levels. 
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